Novartis' Ultibro Breezhaler significantly improved COPD patients' lung function after direct switch from Seretide29 Nov 2017
Study provides further evidence that it is possible to reduce the burden of long-term inhaled steroids in many COPD patients.
Novartis has announced positive results from the FLASH study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide (salmeterol/fluticasone) 50/500 mcg to Ultibro Breezhaler (indacaterol/glycopyrronium) 110/50 mcg. The study met the primary endpoint demonstrating that switching patients to Ultibro Breezhaler resulted in significantly improved lung function (trough FEV1).
The superiority of once-daily Ultibro Breezhaler over twice-daily salmeterol/fluticasone in improving lung function and reducing the rate of COPD exacerbations has been established in previous studies. The FLASH study is the first randomized controlled trial to confirm the benefits of directly switching patients from this steroid-containing therapy to the dual bronchodilator, therefore avoiding the side effects of the long-term use of inhaled corticosteroids. Importantly, patients were switched without a wash-out period to mimic clinical practice.
"It has already been established that Ultibro Breezhaler improves patients' lung function when directly compared to Seretide in clinical trials," said Shreeram Aradhye, Chief Medical Officer and Global Head of Medical Affairs for Novartis Pharmaceuticals. "This new research is important because it shows that this benefit also exists when directly switching patients from Seretide to Ultibro Breezhaler as would happen in everyday clinical practice. The FLASH study provides further evidence that it is possible to reduce the burden of long-term inhaled steroids in many COPD patients, as recommended by global treatment guidelines".
These results further reinforce the latest GOLD recommendations, which support the use of dual bronchodilation for the majority of symptomatic COPD patients and limit the use of steroid-containing therapies to specific patient types.
Importantly, the data also indicated that the safety and tolerability profiles of the two treatments were similar.
The FLASH study results were presented at the Asian Pacific Society of Respirology (APSR) Congress in Sydney, Australia (23-26 November 2017).
Spanish CDMO working ahead of EU serialisation deadline
6 Dec 2018
Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.Read more
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases
5 Dec 2018
The financing will power the global commercial launch of the company's Fluidity One system.Read more
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
4 Dec 2018
The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.Read more
NIH to evaluate effectiveness of male contraceptive skin gel
28 Nov 2018
The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.Read more
QPS expands US-based Phase I clinical trial capabilities
27 Nov 2018
Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.Read more
Grant winners to investigate continuous manufacturing for gene therapies
26 Nov 2018
Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.Read more
Proprietary nasal delivery formulation of diazepam reaches NDA
7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.Read more
Plasticell receives EU funding to advance neurodegenerative disease research
1 Nov 2018
Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.Read more
Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology
30 Oct 2018
Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.Read more
SIRIO Pharma opens multimillion gummy production plant
18 Oct 2018
The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation